Completed Pregnancy, Children & Inherited Conditions Diabetes, Hormones & Metabolism

Does progesterone prophylaxis to prevent preterm labour improve outcome? (OPPTIMUM)

In plain English

AI plain-English summary

A daily progesterone pessary could prevent preterm birth and improve long-term health outcomes for babies born early. Preterm delivery is the leading cause of death and disability among UK newborns, yet no drug has been proven to improve outcomes by stopping labour from starting early. Recent evidence suggests progesterone may cut the risk of preterm delivery, but it remains unclear whether this translates into healthier babies and children. This trial tests whether progesterone given to high-risk pregnant women from mid-pregnancy onward reduces preterm birth, improves the baby’s immediate health—including brain damage and lung disease—and boosts cognitive development at age two. The researchers will also calculate whether the treatment saves NHS money overall. If successful, the research could change standard maternity care, giving clinicians a simple, low-cost tool to prevent preterm labour and its devastating consequences. For families, this means fewer babies dying or growing up with disabilities. For the NHS, it could reduce the long-term costs of caring for premature infants. The study directly addresses a critical gap: proving that preventing preterm birth actually improves the child’s life, not just the timing of delivery.

View original technical description
Preterm delivery is the biggest single cause of death and disability amongst babies born in the UK. At present, no drug treatment has been demonstrated to improve the outcome for babies by preventing the onset of preterm labour. It has recently been shown that a natural hormone called progesterone may reduce the risk of preterm delivery by around 50%. In the proposed study, we will confirm or refute this effect on preterm delivery and more importantly determine whether it improves the outcome for the baby and child. Pregnant women at high risk of preterm delivery who agree to take part will be given either a progesterone or a placebo (dummy) pessary daily from 22-24 until 34 weeks of pregnancy. We will record when the woman gives birth, whether the baby survives, and if so its immediate health (including any brain damage or lung disease) and health at two years of age using a developmental assessment scale. We will also calculate the costs of NHS treatment. We hope to show that progesterone treatment reduces the risk of preterm birth, that it improves baby’s immediate health, it is associated with improved thinking ability of the child at two years, and it reduces NHS costs overall.

View the original record at the funder ↗

Researchers

Andrew Shennan (Co-Investigator)Jane Norman (Principal Investigator)John Norrie (Co-Investigator)Neil Marlow (Co-Investigator)Neil Sebire (Co-Investigator)Phillip Bennett (Co-Investigator)Stavros Petrou (Co-Investigator)Stephen Robson (Co-Investigator)Steven Thornton (Co-Investigator)Tina Lavender (Co-Investigator)

Related Research

Grants with similar aims, by meaning.

Effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding: A randomised placebo-controlled trial (PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial)
Long-term health assessment of children following first trimester progesterone treatment in the PRISM trial
Prediction of preterm birth study (PROPER)
Pre-eclampsia in Hospital: Early Induction or Expectant management (PHOENIX)
Three-arm randomised trial of Arabin pessary, cervical cerclage and progesterone to prevent spontaneous preterm birth in an asymptomatic high risk cohort: a feasibility study

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.